No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Care Facilities
Founded in 1984 and headquartered in Cheongju-si, South Korea, HK inno.N Corporation operates as a pharmaceutical enterprise. The company boasts a comprehensive portfolio of prescription medications designed to address a wide array of medical conditions. These include treatments for various infectious diseases, such as those caused by gram-positive and gram-negative bacteria, vancomycin-resistant Enterococcus faecium, acute bacterial sinusitis, bronchitis, and pneumonia. Their therapeutic offerings also extend to chronic illnesses like anemia, diabetes, hypertension (including cases with dyslipidemia), and hypercholesterolemia (covering primary and homozygous familial types), alongside solutions for hemodialysis. The firm develops drugs for gastrointestinal disorders such as GERD, EE, NERD, GU, and H. Pylori infections. In the oncology sector, HK inno.N provides treatments for non-small cell lung cancer, colorectal cancer, and both pleural and general mesothelioma. Additionally, they offer nutritional and intravenous therapeutic solutions. Beyond pharmaceuticals, the corporation supplies health and wellness products, including hangover relief drinks, ready-to-drink beverages, health supplements, functional foods, and active pharmaceutical ingredients. Its beauty division markets products under the bewants, ScalpMed, and KLEDERMA RX brands. The company maintains an international presence, exporting its diverse range of products to markets across Japan, Southeast Asia, Latin America, Europe, and the Middle East.
www.inno-n.comNo one on the platform currently holds 195940.KQ.
No tracked institution reports a position in 195940.KQ as of their last filing.
No one on the platform has traded 195940.KQ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.2% | 4.1% | — | — | — | |
| Rev. Growth % | 18.5% | 12.2% | ||||
| Profit Margin % | 7.1% | 5.5% | ||||
| Free Cash Flow Margin % | 6.9% | 2.7% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.10T | +4.2% | $3228.33 | $2820.85–$3818.23 | — | 12 |
| 2027 | $1.18T | +6.8% | $3854.15 | $3322.30–$4435.83 | — | 12 |
| 2028 | $1.26T | +6.9% | $4559.37 | $4341.23–$5130.77 | — | 6 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $721.00 | $482.67 | -33.1% |
| 2024-10-30 | $817.03 | $512.00 | -37.3% |
| $28950.00 |
| -2.03% |
| $674.7B |
| — |
| 166090.KQHana Materials Inc. | $52800.00 | +0.57% | $1.02T | — |
| 222800.KQSIMMTECH Co., Ltd. | $130700.00 | +4.14% | $4.88T | — |
Source: Financial Modeling Prep · peers by sector/industry